A clinical trial of Crenezumab, made by Genentech, will focus largely on people in a large Colombian family who are genetically destined to suffer from the disease but who do not yet have any symptoms.
In this Mayo Clinic Radio Health Minute, Dr. Nilufer Taner explains how our body's immune system could help ward off Alzheimer's disease. To listen, click the link below. Immune System and Alzheimer's
The Alzheimer's Prevention Initiative (API) trial in cognitively healthy individuals has reached a significant milestone with the first participants in Colombia receiving doses of an experimental anti-amyloid antibody, crenezumab de...
While the drug, crenezumab, did not slow progression of the disease over all, at the highest doses it seemed to delay a decline in mental ability in patients with mild Alzheimer’s.